Kurs
+0,95%
Likviditet
0,02 MSEK
Kalender
| Est. tid* | ||
| 2027-02-17 | 08:30 | Bokslutskommuniké 2026 |
| 2026-11-18 | 08:30 | Kvartalsrapport 2026-Q3 |
| 2026-08-19 | 08:30 | Kvartalsrapport 2026-Q2 |
| 2026-05-20 | 08:30 | Kvartalsrapport 2026-Q1 |
| 2026-05-08 | N/A | X-dag ordinarie utdelning ERMA 0.00 SEK |
| 2026-04-07 | - | Extra Bolagsstämma 2026 |
| 2026-03-18 | - | Bokslutskommuniké 2025 |
| 2025-12-02 | - | Extra Bolagsstämma 2025 |
| 2025-11-19 | - | Kvartalsrapport 2025-Q3 |
| 2025-08-20 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-21 | - | Kvartalsrapport 2025-Q1 |
| 2025-05-09 | - | X-dag ordinarie utdelning ERMA 0.00 SEK |
| 2025-04-08 | - | Årsstämma |
| 2025-02-19 | - | Bokslutskommuniké 2024 |
| 2024-11-20 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-21 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-05 | - | Årsstämma |
| 2024-05-23 | - | X-dag ordinarie utdelning ERMA 0.00 SEK |
| 2024-05-22 | - | Kvartalsrapport 2024-Q1 |
| 2024-03-04 | - | Extra Bolagsstämma 2023 |
| 2024-02-21 | - | Bokslutskommuniké 2023 |
| 2023-11-22 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-23 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-30 | - | Årsstämma |
| 2023-05-31 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-25 | - | X-dag ordinarie utdelning ERMA 0.00 SEK |
| 2023-02-15 | - | Bokslutskommuniké 2022 |
| 2022-12-23 | - | Extra Bolagsstämma 2022 |
| 2022-11-16 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-17 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-19 | - | X-dag ordinarie utdelning ERMA 0.00 SEK |
| 2022-05-18 | - | Årsstämma |
| 2022-05-18 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-16 | - | Bokslutskommuniké 2021 |
| 2021-11-10 | - | Kvartalsrapport 2021-Q3 |
| 2021-11-03 | - | Extra Bolagsstämma 2021 |
| 2021-08-11 | - | Kvartalsrapport 2021-Q2 |
| 2021-06-23 | - | Årsstämma |
| 2021-05-20 | - | X-dag ordinarie utdelning ERMA 0.00 SEK |
| 2021-05-19 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-17 | - | Bokslutskommuniké 2020 |
| 2020-11-11 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-12 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-29 | - | X-dag ordinarie utdelning ERMA 0.00 SEK |
| 2020-06-26 | - | Årsstämma |
| 2020-05-20 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-20 | - | Bokslutskommuniké 2019 |
| 2019-11-13 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-14 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-27 | - | X-dag ordinarie utdelning ERMA 0.00 SEK |
| 2019-05-24 | - | Årsstämma |
| 2019-05-24 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-21 | - | Bokslutskommuniké 2018 |
| 2018-11-07 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-15 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-17 | - | X-dag ordinarie utdelning ERMA 0.00 SEK |
| 2018-05-16 | - | Årsstämma |
| 2018-05-16 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-15 | - | Bokslutskommuniké 2017 |
| 2017-11-15 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-16 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-18 | - | X-dag ordinarie utdelning ERMA 0.00 SEK |
| 2017-05-17 | - | Årsstämma |
| 2017-05-17 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-15 | - | Bokslutskommuniké 2016 |
| 2016-10-27 | - | Kvartalsrapport 2016-Q3 |
| 2016-07-29 | - | Kvartalsrapport 2016-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
On 7 April 2026, an extraordinary general meeting and first control meeting was held in Enorama Pharma AB (publ), reg. no. 556716-5591 ("Enorama Pharma" or the "Company"). Below is a summary of the resolution that was passed.
Resolution on continuing the Company's operations
The general meeting resolved, in accordance with the board of directors' primary proposal, that the Company shall continue its operations and not go into liquidation.
The board of directors considers that the discussions regarding the injection of capital and various capital raising measures from existing and new investors will enable the Company's equity to be restored within the time prescribed by the Swedish Companies Act (Sw. aktiebolagslagen) (8 months).
The resolution means that the Company shall convene a new general meeting within eight months from today's date in order to, at a second control meeting, reconsider the issue of Enorama Pharma going into liquidation. Prior to the second control meeting, the board of directors will prepare a new balance sheet for liquidation purposes and have it reviewed by the Company's auditor. If the capital has not been restored to at least the registered share capital, the Company is obliged to enter into liquidation.
The board of directors had also prepared a secondary proposal for a resolution on liquidation in accordance with the Swedish Companies Act (Sw. aktiebolagslagen). However, this proposal was not considered since the general meeting resolved to continue the operations.
CONTACT
Enorama Pharma AB (publ)
Bengt Jönsson, CEO
info@enorama.se
Strandvägen 7A, 114 51 Stockholm
www.enorama.se
Enorama Pharma AB (publ) is listed on Nasdaq First North Growth Market.
The Company's Certified Adviser is Tapper Partners AB, +46 (0)70 44 010 98, ca@tapperpartners.se.
ABOUT ENORAMA PHARMA
Enorama Pharma's vision is to be a leading global manufacturer and supplier of consumer-friendly, oral nicotine products. The Company intends to expand through product and brand development and by establishing strategically important partnerships. For more information, visit www.enorama.se.